QMS Medical Allied posted its Q1 FY26 results on 18th August 2025, reporting a strong performance across revenue and profit metrics. The company’s consolidated figures reflected robust growth, with revenue rising more than 53% year-on-year (YoY) and profit after tax (PAT) climbing over 22% YoY. While the operational growth remains promising, the stock has yet to deliver returns for investors in the longer horizon.
QMS Medical Allied Q1 FY26 Performance
During the quarter ended 30th June 2025, QMS Medical Allied reported consolidated revenue of ₹46.50 crore, a 53.11% increase compared to ₹30.37 crore in the same quarter last year.
On the profitability front, consolidated PAT stood at ₹2.93 crore, up 22.25% YoY compared to ₹2.40 crore in Q1 FY25. Profit before tax (PBT) also increased to ₹6.76 crore from ₹4.95 crore a year earlier.
This performance highlights the company’s improving operational efficiency and revenue momentum.
Standalone vs. Consolidated Figures
The company’s standalone results also indicated positive growth:
-
Standalone Revenue rose to ₹42.32 crore in Q1 FY26, compared to ₹30.37 crore in Q1 FY25, a 39.37% YoY increase.
-
Standalone PAT came in at ₹2.70 crore, up from ₹2.40 crore last year, reflecting a 12.48% YoY increase.
-
Standalone PBT increased to ₹6.42 crore from ₹4.95 crore.
While both consolidated and standalone results show strong growth, the consolidated numbers reflect a sharper profit jump, reinforcing the benefits of synergy across business units.
QMS Medical Allied Q1 FY26 Highlights
-
Consolidated Revenue: ₹46.50 crore (Q1 FY26) vs. ₹30.37 crore (Q1 FY25)
-
Consolidated PAT: ₹2.93 crore (Q1 FY26) vs. ₹2.40 crore (Q1 FY25), 22.25% growth YoY
-
Standalone Revenue: ₹42.32 crore (Q1 FY26) vs. ₹30.37 crore (Q1 FY25), 39.37% growth YoY
-
Standalone PAT: ₹2.70 crore (Q1 FY26) vs. ₹2.40 crore (Q1 FY25), 12.48% growth YoY
The double-digit revenue and profit growth underlines a strong start to FY26 for the company.
Share Price Performance
Despite the solid Q1 numbers, QMS Medical Allied shares have struggled to generate wealth for investors in the long run.
-
On 20th August 2025, the stock opened at ₹80.00 per share and is currently trading at ₹81.00, marginally below its opening price.
-
Over the past 1 year, the stock has delivered -30.53% returns.
-
Over a 5-year period, the return stands at -54.96%, indicating persistent underperformance.
-
Since listing (maximum timeframe), the share has yielded -54.96% returns.
This gap between business growth and share price performance highlights the market’s cautious stance on the stock.
Analyst Expectations
Following the Q1 FY26 results, analysts remain cautiously optimistic about QMS Medical Allied’s prospects. Based on the company’s revenue and profit growth momentum, analysts have set an upside target of ₹100.20 per share for the coming year.
On the downside, if broader market weakness or company-specific risks weigh on sentiment, the stock could test levels of ₹70.10 per share.
While the Q1 results suggest financial strength, analysts caution that investors must factor in market volatility, sector risks, and the company’s historical underperformance before making investment decisions.
Conclusion
QMS Medical Allied delivered a strong Q1 FY26, with 53.11% revenue growth and 22.25% profit growth YoY, marking a solid start to the financial year. However, despite improving fundamentals, the share price continues to lag, reflecting skepticism in the market.
For investors, the stock offers potential upside if growth sustains and sentiment improves, but caution is warranted given the history of underperformance. The coming quarters will be critical in determining whether QMS Medical Allied can translate its operational gains into shareholder value.
